Magnetic eye cells tested in cataract surgery safety trial

NCT ID NCT05587205

Recruiting now Disease control Sponsor: Asociación para Evitar la Ceguera en México Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new treatment called EO2002, which uses magnetic human corneal cells injected into the eye during or after cataract surgery. The goal is to see if it is safe and tolerable for patients with low corneal cell counts. The study involves 32 participants and compares EO2002 to a sham (fake) injection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Magnetic human corneal endothelial cells (EO2002)
What this could lead to: If safe, this could lead to a new way to repair the cornea after cataract surgery, potentially reducing the need for corneal transplants.
What could go wrong: This is a very early Phase 1 trial with only 32 people, focused on safety. It is too small to prove effectiveness, and the cells may not work as hoped or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CATARACT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract Corneal Endothelial Cell Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CATARACT ENDOTHELIAL CELL LOSS, CORNEAL

Contacts and locations

Locations

Asociacion para Evitar la Ceguera en Mexico
RECRUITING

Mexico City, Mexico City, 04030, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.